Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | EDNRB | P24530 | 2/20 | 0.48 |
| ▸ | EDNRA | P25101 | 2/20 | 0.48 |
| ▸ | TNKS | O95271 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316764 | 0.93 | PTGS2 (0.87) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL8700474 | 0.87 | PTGS2 (0.77) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL4789136 | 0.84 | PTGS2 (0.72) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL30009937 | 0.80 | PTGS2 (0.66) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL404584 | 0.80 | PTGS2 (0.66) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL10736364 | 0.78 | PTGS2 (0.69) | PTGS2MEN1KMT2AADORA3KDM4E | |
| SCHEMBL592300 | 0.75 | PTGS2 (0.65) | PTGS2MEN1KMT2AADORA3KDM4E | |
| SCHEMBL29629010 | 0.74 | PTGS2 (0.58) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL2692579 | 0.74 | CA12 (0.59) | PTGS2PTPRCNPC1RAB9AMEN1 | |
| SCHEMBL25440225 | 0.72 | RAB9A (0.65) | PTGS2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1441721-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GmbH (DE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003039539-A2 | USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | claimed |
| WO-2008140251-A2 | CYCLOOXYGENASE-2 INHIBITORS | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140251-A2 | CYCLOOXYGENASE-2 INHIBITORS | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2008-11-20 | — | — | WO | disclosed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | PTGS2 247/4885PTPRC 1514/4885NPC1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.